Literature DB >> 12542923

The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations.

John E Mazuski1, Robert G Sawyer, Avery B Nathens, Joseph T DiPiro, Moshe Schein, Kenneth A Kudsk, Charles Yowler.   

Abstract

Revised guidelines for the use of antimicrobial therapy in patients with intra-abdominal infections were recently developed by the Therapeutic Agents Committee of the Surgical Infection Society (Mazuski et al., Surg Infect 2002;3:161-173). These were based, insofar as possible, on evidence published over the past decade. The objective of this document is to describe the process by which the Committee identified and reviewed the published literature utilized to develop the recommendations and to summarize the results of those reviews. English-language articles published between 1990 and 2000 related to antimicrobial therapy for intra-abdominal infections were identified by a systematic MEDLINE search and an examination of references included in recent review articles. If current literature with regard to a specific issue was lacking, relevant articles published prior to 1990 were identified. All prospective randomized controlled trials, as well as other articles selected by the Committee, were evaluated individually and collectively. Data with regard to patient numbers, types of infections, and results of interventions were abstracted. Studies were categorized according to their design, and all included trials were graded according to quality. On the basis of this evidence, the Committee formulated recommendations for antimicrobial therapy for intra-abdominal infections and graded those recommendations. After receiving comments from invited reviewers and the general membership of the Society, the guidelines were finalized and submitted to the Council of the Surgical Infection Society for approval. The final recommendations related to the selection of patients needing therapeutic antimicrobials, acceptable antimicrobial regimens, duration of antimicrobial use, and the identification and treatment of higher-risk patients. Although numerous publications pertaining to these topics were identified, but nearly all of the prospective randomized controlled trials represented comparisons of different antimicrobial regimens for the treatment of intra-abdominal infections. A few prospective trials evaluated the need for therapeutic antimicrobial therapy in patients with peritoneal contamination following abdominal trauma. The quality of these prospective trials was highly variable. Many did not limit enrollment to patients with complicated intra-abdominal infections, lacked blinding of treatment assignment, did not provide a complete description of the criteria used to determine therapeutic success or failure, failed to identify the reasons why patients were excluded from analysis, or did not include an intention-to-treat analysis. For many issues, no prospective randomized controlled trials were encountered, and guidelines had to be formulated using evidence from studies with historical controls or uncontrolled data, or on the basis of expert opinion

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12542923     DOI: 10.1089/109629602761624180

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  21 in total

1.  Are enterococci playing a role in postoperative peritonitis in critically ill patients?

Authors:  P Seguin; C Brianchon; Y Launey; B Laviolle; N Nesseler; P-Y Donnio; Y Malledant
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-12       Impact factor: 3.267

Review 2.  [Antimicrobial and antimycotic therapy of intra-abdominal infections].

Authors:  P Kujath; M Hoffmann; A Rodloff
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

3.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.

Authors:  Mark A Malangoni; James Song; Janet Herrington; Shurjeel Choudhri; Peter Pertel
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

5.  Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.

Authors:  Philippe Montravers; Annie Chalfine; Remy Gauzit; Alain Lepape; Jean Pierre Marmuse; Corinne Vouillot; Claude Martin
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

6.  Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.

Authors:  Zhangjing Chen; Jufang Wu; Yingyuan Zhang; Junming Wei; Xisheng Leng; Jianwei Bi; Rong Li; Lunan Yan; Zhiwei Quan; Xiaoping Chen; Yunsong Yu; Zhiyong Wu; Dawei Liu; Xiaochun Ma; Robert Maroko; Angel Cooper
Journal:  BMC Infect Dis       Date:  2010-07-21       Impact factor: 3.090

7.  Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"?

Authors:  Brian R Swenson; Rosemarie Metzger; Traci L Hedrick; Shannon T McElearney; Heather L Evans; Robert L Smith; Tae W Chong; Kimberley A Popovsky; Timothy L Pruett; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2009-02       Impact factor: 2.150

8.  Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections.

Authors:  Lin M Riccio; Kimberley A Popovsky; Tjasa Hranjec; Amani D Politano; Laura H Rosenberger; Kristin C Tura; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2014-05-13       Impact factor: 2.150

9.  Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

Authors:  Mao Mao An; Zui Zou; Hui Shen; Jun Dong Zhang; Meng Li Chen; Ping Liu; Rui Wang; Yuan Ying Jiang
Journal:  BMC Infect Dis       Date:  2009-12-02       Impact factor: 3.090

10.  T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam.

Authors:  Fausto Catena; Carlo Vallicelli; Luca Ansaloni; Massimo Sartelli; Salomone Di Saverio; Riccardo Schiavina; Eddi Pasqualini; Annalisa Amaduzzi; Federico Coccolini; Michele Cucchi; Daniel Lazzareschi; Gian Luca Baiocchi; Antonio D Pinna
Journal:  BMC Gastroenterol       Date:  2013-04-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.